EyePoint Pharmaceuticals (NASDAQ:EYPT) +11% after-hours on news it signed an exclusive license agreement
with Equinox Science to develop vorolanib, a tyrosine kinase inhibitor,
for the treatment of wet age-related macular degeneration, diabetic
retinopathy and retinal vein occlusion.
EyePoint is developing vorolanib as EYP-1901,
utilizing a miniaturized, injectable, sustained-release intravitreal
drug delivery system with a six-month duration.
The company says it recently completed a positive
Type B pre-Investigational New Drug meeting with the Food and Drug
Administration clarifying the pathway for a phase 1 clinical trial,
which it expects will provide data in H2 2021.
https://seekingalpha.com/news/3537714-eyepoint-pharma-inks-exclusive-license-deal-equinox-science
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.